Dyne Therapeutics reports FY2022 net loss $168.1M; cash $256M; data readouts H2 2023

Dyne Therapeutics, Inc.

Cash, cash equivalents and marketable securities $256.0M as of Dec 31, 2022; expected to fund operations through 2024.
Net loss Q4 2022 $38.8M ($0.74/share) vs $51.8M ($1.00/share) in Q4 2021; full year net loss $168.1M ($3.23/share).
R&D expenses FY2022 $142.8M, up from $121.3M in FY2021; G&A expenses $28.2M vs $28.7M.
Enrollment continues in ACHIEVE (DYNE-101 in DM1) and DELIVER (DYNE-251 in DMD) Phase 1/2 registrational trials.
Initial data from MAD placebo-controlled portions of both trials anticipated in second half of 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Dyne Therapeutics, Inc. reported the quarter ended December 31, 2022 results: net income Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share., EPS $0.74 per basic and diluted share.

Period: the quarter ended December 31, 2022
Net income: Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share.
EPS: $0.74 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Dyne Therapeutics, Inc. reported the year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share., EPS $3.23 per basic and diluted share.

Period: the year ended December 31, 2022
Net income: Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share.
EPS: $3.23 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005714

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.